RosengartTK, LeeLY, PatelSR, et al.Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEFG 121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation, 1999; 100:468–474.
2.
PennMS, MendelsohnFO, SchaerGL, et al.An open label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res, 2013; 112:816–825.
3.
GrossmanPM, HanZ, PalasisM, et al.Incomplete retention after direct myocardial injection. Catheter Cardiovasc Intervent, 2002; 55:392–397.
4.
LogeartD, HatemSN, HeimburgerM, et al.How to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures?. Hum Gene Ther, 2001; 12:1601–1610.
